MX2021002967A - Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3. - Google Patents
Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3.Info
- Publication number
- MX2021002967A MX2021002967A MX2021002967A MX2021002967A MX2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A MX 2021002967 A MX2021002967 A MX 2021002967A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disease
- ccr3
- inhibitors
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a método para mejorar enfermedades neurodegenerativas con agentes moduladores de CCR3; los métodos incluyen administrar una cantidad terapéuticamente efectiva del agente modulador de CCR3 al sujeto, con una mejora concomitante en la función cognitiva, motora u otra función afectada de manera neurodegenerativa; las enfermedades cognitivas y motoras en las que los métodos de la invención pueden mejorar la cognición incluyen la enfermedad de Alzheimer, enfermedad de Parkinson, demencia frontotemporal, enfermedad de Huntington, esclerosis lateral amiotrófica, esclerosis múltiple, glaucoma, distrofia miotónica, demencia vascular, parálisis supranuclear progresiva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737017P | 2018-09-26 | 2018-09-26 | |
PCT/US2019/052995 WO2020069008A1 (en) | 2018-09-26 | 2019-09-25 | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002967A true MX2021002967A (es) | 2021-08-11 |
Family
ID=69953286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002967A MX2021002967A (es) | 2018-09-26 | 2019-09-25 | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3856195A4 (es) |
JP (2) | JP7528065B2 (es) |
KR (1) | KR20210065950A (es) |
CN (1) | CN112789044A (es) |
AU (1) | AU2019346456A1 (es) |
BR (1) | BR112021004938A2 (es) |
CA (1) | CA3111433A1 (es) |
CL (1) | CL2021000724A1 (es) |
CO (1) | CO2021003713A2 (es) |
EA (1) | EA202190463A1 (es) |
IL (1) | IL281578A (es) |
MA (1) | MA53743A (es) |
MX (1) | MX2021002967A (es) |
SG (1) | SG11202102105VA (es) |
TW (1) | TW202027752A (es) |
WO (1) | WO2020069008A1 (es) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
EP1996551A2 (en) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
BRPI1014669A2 (pt) * | 2009-04-22 | 2017-07-18 | Axikin Pharmaceuticals Inc | antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída |
US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
JP2020513005A (ja) * | 2017-04-05 | 2020-04-30 | アルカヘスト,インコーポレイテッド | Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物 |
US11590118B2 (en) * | 2017-04-05 | 2023-02-28 | Alkahest Inc. | Methods and compositions for treating retina-associated disease using CCR3-inhibitors |
-
2019
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en active Application Filing
- 2019-09-25 CA CA3111433A patent/CA3111433A1/en active Pending
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/en active Pending
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko unknown
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 JP JP2021517342A patent/JP7528065B2/ja active Active
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
-
2024
- 2024-07-24 JP JP2024118649A patent/JP2024153742A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7528065B2 (ja) | 2024-08-05 |
BR112021004938A2 (pt) | 2021-06-01 |
SG11202102105VA (en) | 2021-04-29 |
WO2020069008A1 (en) | 2020-04-02 |
EP3856195A4 (en) | 2022-06-22 |
EA202190463A1 (ru) | 2021-06-29 |
IL281578A (en) | 2021-05-31 |
MA53743A (fr) | 2022-01-05 |
EP3856195A1 (en) | 2021-08-04 |
AU2019346456A1 (en) | 2021-04-15 |
CL2021000724A1 (es) | 2021-10-15 |
JP2022502441A (ja) | 2022-01-11 |
CA3111433A1 (en) | 2020-04-02 |
KR20210065950A (ko) | 2021-06-04 |
CN112789044A (zh) | 2021-05-11 |
JP2024153742A (ja) | 2024-10-29 |
CO2021003713A2 (es) | 2021-04-08 |
TW202027752A (zh) | 2020-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011988A (es) | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3. | |
WO2018015573A3 (en) | Trem2 cleavage modulators and uses thereof | |
PH12018502028A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
EA201991756A1 (ru) | Бисгетероарильные производные в качестве модуляторов агрегации белков | |
EA201991755A1 (ru) | Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков | |
EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
MX2021001456A (es) | 2-arilbenzimidazoles como activadores de ppargc1a para tratar enfermedades neurodegenerativas. | |
BR112021002090A8 (pt) | Derivado azabicíclico opticamente ativo | |
CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
MX2017011598A (es) | Metodos para tratar proteinopatias. | |
PH12021552217A1 (en) | Macrocyclic azolopyridine derivatives as eed and prc2 modulators | |
PH12020551779A1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
WO2018013775A3 (en) | Granulin compositions and uses related thereto | |
IL309208A (en) | Neuroactive steroids for the treatment of Alzheimer's disease | |
WO2020117031A3 (en) | Composition and method for inhibiting amyloid beta accumulation and/or aggregation | |
MX2021002967A (es) | Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores ccr3. | |
JP2017519798A5 (es) | ||
EA201991753A1 (ru) | Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков | |
TW200635589A (en) | Therapeutic agents | |
WO2020092102A3 (en) | 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of the m4 muscarinic acetylcholine receptor | |
EA201992188A1 (ru) | Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов | |
MX2022007654A (es) | Compuestos inhibidores de la oga. | |
MA54630B1 (fr) | N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives |